| |
| |
|
| Insider
Information: |
Patni Rajiv |
| Relationship: |
EVP, Chief R&D Officer |
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
89,191 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$1,034,989 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
89,191 |
|
|
| Total
Value |
$1,034,989 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ocera Therapeutics Inc |
OCRX |
Chief Development Offi... |
2015-05-07 |
5,050 |
2015-05-07 |
0 |
Premium* |
|
|
Adamas Pharmaceuticals Inc |
ADMS |
Chief Medical Officer |
2019-04-08 |
49,141 |
2016-03-04 |
0 |
Premium* |
|
|
Portola Pharmaceuticals Inc |
PTLA |
EVP, CMO |
2020-02-28 |
35,000 |
2020-02-28 |
0 |
Premium* |
|
|
Reata Pharmaceuticals Inc |
RETA |
EVP, Chief R&D Officer |
2023-09-26 |
0 |
2023-06-12 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
11 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RETA |
Reata Pharmaceuticals Inc |
EVP, Chief R&D Officer |
• – – |
2023-09-26 |
4 |
D |
$0.00 |
$0 |
D/D |
(45,000) |
0 |
0 |
- |
|
| RETA |
Reata Pharmaceuticals Inc |
EVP, Chief R&D Officer |
• – – |
2023-06-12 |
4 |
A |
$0.00 |
$0 |
D/D |
45,000 |
45,000 |
0 |
- |
|
| PTLA |
Portola Pharmaceuticals I... |
EVP, CMO |
• – – |
2020-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
35,000 |
35,000 |
0 |
- |
|
| ADMS |
Adamas Pharmaceuticals In... |
Chief Medical Officer |
• – – |
2019-04-08 |
4 |
A |
$0.00 |
$0 |
D/D |
30,000 |
49,141 |
0 |
- |
|
| ADMS |
Adamas Pharmaceuticals In... |
Chief Medical Officer |
• – – |
2019-03-20 |
4 |
S |
$8.00 |
$18,992 |
D/D |
(2,374) |
19,141 |
0 |
- |
|
| ADMS |
Adamas Pharmaceuticals In... |
Chief Medical Officer |
• – – |
2018-03-21 |
4 |
S |
$25.94 |
$32,477 |
D/D |
(1,252) |
21,515 |
0 |
- |
|
| ADMS |
Adamas Pharmaceuticals In... |
Chief Medical Officer |
• – – |
2018-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
9,125 |
22,767 |
0 |
- |
|
| ADMS |
Adamas Pharmaceuticals In... |
Chief Medical Officer |
• – – |
2017-03-21 |
4 |
S |
$17.04 |
$12,490 |
D/D |
(733) |
13,642 |
0 |
- |
|
| ADMS |
Adamas Pharmaceuticals In... |
Chief Medical Officer |
• – – |
2017-01-18 |
4 |
A |
$0.00 |
$0 |
D/D |
6,875 |
14,375 |
0 |
- |
|
| ADMS |
Adamas Pharmaceuticals In... |
Chief Medical Officer |
• – – |
2016-03-04 |
4 |
A |
$13.66 |
$102,450 |
D/D |
7,500 |
7,500 |
0 |
- |
|
| OCRX |
Ocera Therapeutics Inc |
Chief Development Officer |
• – – |
2015-05-07 |
4 |
B |
$3.97 |
$20,049 |
D/D |
5,050 |
5,050 |
2.74 |
- |
|
11 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
